BioCardia Management
Management criteria checks 4/4
BioCardia's CEO is Peter Altman, appointed in Jan 2002, has a tenure of 24.17 years. total yearly compensation is $550.92K, comprised of 92% salary and 8% bonuses, including company stock and options. directly owns 2.51% of the company’s shares, worth $318.73K. The average tenure of the management team and the board of directors is 10 years and 6.4 years respectively.
Key information
Peter Altman
Chief executive officer
US$550.9k
Total compensation
| CEO salary percentage | 91.97% |
| CEO tenure | 24.2yrs |
| CEO ownership | 2.5% |
| Management average tenure | 10yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
Catalysts About BioCardia BioCardia develops cell and biotherapeutic delivery therapies aimed at treating cardiovascular disease. What are the underlying business or industry changes driving this perspective?
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
Catalysts About BioCardia BioCardia develops cell therapies and delivery systems for cardiovascular diseases, focusing on heart failure and ischemic heart conditions. What are the underlying business or industry changes driving this perspective?Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
May 14
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns
Oct 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$551k | US$507k | -US$8m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$9m |
| Mar 31 2025 | n/a | n/a | -US$8m |
| Dec 31 2024 | US$639k | US$493k | -US$8m |
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | n/a | n/a | -US$9m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$863k | US$516k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$902k | US$531k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$488k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$883k | US$380k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$747k | US$363k | -US$15m |
Compensation vs Market: Peter's total compensation ($USD550.92K) is about average for companies of similar size in the US market ($USD630.05K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Altman (58 yo)
Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 24.2yrs | US$550.92k | 2.51% $ 318.7k | |
| Chief Financial Officer | 10yrs | US$395.94k | 0.70% $ 89.2k | |
| Senior Vice President of Devices | 5.4yrs | US$281.87k | 0.29% $ 37.0k | |
| Investor Relations Executive | no data | no data | no data |
Experienced Management: BCDA's management team is seasoned and experienced (10 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 24.2yrs | US$550.92k | 2.51% $ 318.7k | |
| Independent Director | 15.2yrs | US$74.98k | 0.033% $ 4.2k | |
| Independent Director | less than a year | US$17.72k | no data | |
| Independent Director | 2.4yrs | US$61.48k | 0.12% $ 15.2k | |
| Independent Director | 24.2yrs | US$53.98k | 6.53% $ 828.6k | |
| Independent Director | 6.4yrs | US$58.98k | 1% $ 127.2k | |
| Independent Chairman | 6.4yrs | US$107.48k | 5.81% $ 737.8k |
Experienced Board: BCDA's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/30 09:38 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCardia, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Joseph Pantginis | H.C. Wainwright & Co. |